Drug
TNX-103
TNX-103 is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_3
3
100%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
3(100.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Recruiting2
Enrolling by invitation1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 33 (100.0%)
Trials by Status
enrolling_by_invitation133%
recruiting267%
Recent Activity
2 active trials
Showing 3 of 3
enrolling_by_invitationphase_3
Long-Term Open-Label Extension Study of Oral Levosimendan
NCT07436689
recruitingphase_3
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398
recruitingphase_3
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
NCT05983250
Clinical Trials (3)
Showing 3 of 3 trials
NCT07436689Phase 3
Long-Term Open-Label Extension Study of Oral Levosimendan
NCT07288398Phase 3
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT05983250Phase 3
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3